论文部分内容阅读
用微量分光光度法对正常人、肝细胞癌(HCC)、良性肝病和其它疾病患者血清α—L-岩藻糖苷酶(SAFU)的活性进行了测定。结果表明,HCC患者SAFU活性(765.10±289.00nmol/ml·h) 明显高于正常人(409.33±83.95nmol/ml·h),67.80％的HCC患者SAFU活性高于正常值上限,而且与血清甲胎蛋白(AFP)无关。虽然相当一部分肝炎和肝硬化患者SAFU也增高,但这些病人往往伴有明显的肝功能异常。提示:SAFU活性可作为HCC的又一诊断指标。
The activity of serum α-L-fucosidase (SAFU) in patients with normal, hepatocellular carcinoma (HCC), benign liver disease and other diseases was determined by microspectrophotometry. The results showed that SAFU activity in HCC patients (765.10±289.00 nmol/ml·h) was significantly higher than that in normal subjects (409.33±83.95 nmol/ml·h). The activity of SAFU in 67.80% HCC patients was higher than the upper limit of normal, and it was associated with serum A. There is no relationship between fetal protein (AFP). Although a considerable number of patients with hepatitis and cirrhosis have increased SAFU, these patients are often accompanied by significant abnormal liver function. Tip: SAFU activity can be used as another diagnostic indicator of HCC.